Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic Evaluation of Fondaparinux vs UFH in Pulmonary Embolism
NCT00377091Phase 4Withdrawn
- Sponsor
- University of Minnesota
- Start
- Jun 2007
- Primary completion
- Nov 2007
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 4 trial of fondaparinux in pulmonary embolism (PE), sponsored by University of Minnesota. Planned start Jun 2007; status: withdrawn.
02
Drugs
fondaparinux
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00377091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377091.